Floatz Rating
BB67/100
Confidence
Indicative
Sponsor
Beni-Suef University
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
63High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07604779CT.gov Enhancing PCOS Management for Better Outcomes of Intracytoplasmic Sperm Injection | — | Active Not Recruiting | — | — | — |
NCT05394142CT.gov A Clinical Trial to Evaluate the Efficacy, Tolerability, and Safety of a Fixed Dose Combination of Spironolactone, Pioglitazone & Metformin (SPIOMET) in Polycystic Ovary Syndrome (PCOS) | — | Unknown | — | — | — |
NCT05519813CT.gov Effects of Pioglitazone Combined With Metformin on Gonadal and Metabolic Profiles in Chinese Nonobese PCOS Patients. | — | Unknown | — | — | — |
NCT04867252CT.gov Effects of Combined Resveratrol and Myo-inositol on Altered Metabolic, Endocrine Parameters and Perceived Stress in Patients With Polycystic Ovarian Syndrome | — | Completed | — | — | — |
NCT04113889CT.gov Effects of Triple Drug Cocktail Therapy on Metabolic, Endocrine Alterations and Perceived Stress in Patients With Poly Cystic Ovary Syndrome | — | Completed | — | — | — |
NCT02689843CT.gov Effects of Cyproterone Compound-spironolactone, Metformin and Pioglitazone on Inflammatory Markers in PCOS | — | Completed | — | — | — |
NCT02341703CT.gov Ovulation Induction in Clomiphene Citrate Resistant PCO Women | — | Completed | — | — | — |
NCT01909141CT.gov Ovulation Induction in Women With Clomiphene Citrate Resistant PCOS | — | Completed | — | — | — |
NCT00868140CT.gov Effects of Pioglitazone on Insulin and Glucose Metabolism in Women With Polycystic Ovary Syndrome (PCOS) | — | Terminated | — | — | — |
NCT00694759CT.gov Cortisol Regulation in Polycystic Ovary Syndrome (PCOS) | — | Completed | — | — | — |
Show 2 more trialsShow fewer
NCT00203996CT.gov Polycystic Ovary Syndrome (PCOS) and Sleep Apnea | — | Terminated | — | — | — |
NCT00145340CT.gov Pioglitazone Treatment in Polycystic Ovary Syndrome | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Polycystic Ovary Syndrome
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Pioglitazone (this asset) | Beni-Suef University | Approved | BB · 67 |
| Liraglutide | Peking University Third Hospital | P4 | BBB |
| Human Chorionic Gonadotropin | Eman Basuni Ebrahim Mowad | P4 | BBB |
| Semaglutide | Methodist Health System | P4 | BBB |
| Drospirenone | Ege University | P4 | BBB |
| Follitropin Beta | Universitair Ziekenhuis Brussel | P4 | BBB |
| Ethinyl Estradiol | Ege University | P4 | BBB |
| Glucophage | Near East University, Turkey | P4 | BBB |
| Clomiphene Citrate | HITEC-Institute of Medical Sciences | P4 | BBB |
+41 more in the Polycystic Ovary Syndrome cohort
Other indications for Pioglitazone
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Diabetes Mellitus | — | P4 | BBB · 79 |
| Metabolic Dysfunction-Associated Steatohepatitis | — | P4 | BBB · 75 |
| Abdominal Obesity-Metabolic Syndrome | — | P4 | BBB · 73 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Pioglitazone in Polycystic Ovary Syndrome. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/pioglitazone-polycystic-ovary-syndrome
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →